Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2020

01-12-2020 | Human Immunodeficiency Virus | Research

Diabetes mellitus and its associated risk factors in patients with human immunodeficiency virus on anti-retroviral therapy at referral hospitals of Northwest Ethiopia

Authors: Alemu Gebrie, Bekele Tesfaye, Tensae Gebru, Fentahun Adane, Worku Abie, Mekonnen Sisay

Published in: Diabetology & Metabolic Syndrome | Issue 1/2020

Login to get access

Abstract

Background

The use of highly active anti- retroviral therapy (HAART) as well as human immunodeficiency virus (HIV) per se have been shown to be related with diabetes among patients living with HIV. There is limited evidence on the prevalence of diabetes among HIV-infected patients in developing countries like Ethiopia. Therefore, the aim of this study is to determine the prevalence of diabetes among patients living with HIV/AIDS at referral hospitals of Northwest Ethiopia.

Materials and methods

a hospital based cross-sectional study was conducted at referral hospitals of Northwest Ethiopia between February 2019 and April 2019. Using WHO stepwise approach, sociodemographic, behavioral and clinical data were collected from 407 included adult patients. Simple random sampling methods was used to select the study participants. Lipid profiles, fasting blood sugar as well as anthropometric indicators were also measured. SPSS version 25 was used for analysis of data; bivariate and multivariate binary logistic regression analysis was performed.

Result

From a total of 415 patients living with HIV deemed eligible for inclusion, 407 with complete data were included in the final analysis giving a response rate of 98%. From 407 study subjects included in the analysis, 161 (39.6%) were men. The prevalence of diabetes mellitus was found to be 8.8% (95% CI 6.05, 11.55). Multivariate logistic regression analysis revealed that age [AOR (95% CI) 1.04 (1.001,1.084), p < 0.05], educational status [AOR (95% CI) 6.27 (1.72, 22.85), p < 0.05, diploma; AOR (95% CI) 9.64 (2.57, 36.12), p < 0.05, degree and above], triglyceride level [AOR (95% CI) 1.007 (1.003, 1.010), p < 0.01] have shown statistically significant association with odds of diabetes mellitus.

Conclusion

The prevalence of diabetes was notably high in patients living with HIV/AIDS. Factors such as increased age, educational status and higher level of serum triglyceride were found to contribute to this high prevalence of diabetes.
Literature
1.
2.
3.
EDHS. Ethiopia Demographic and Health Survey, 2016 HIV prevalence report: Central Statistical Authority; Addis Ababa, Ethiopia, and Rockville, Maryland, USA; CSA and ICF; 2016.
4.
Bishu KG, Jenkins C, Yebyo HG, Atsbha M, Wubayehu T, Gebregziabher M. Diabetes in Ethiopia: a systematic review of prevalence, risk factors, complications, and cost. Obesity Medicine. 2019;15:100132.CrossRef
5.
Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Phys AIDS Care. 2012;11(1):20–5.CrossRef
6.
Nüesch R, Wang Q, Elzi L, Bernasconi E, Weber R, Cavassini M, Vernazza P, Thurnheer MC, Calmy A, Battegay M. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). JAIDS. 2013;62(4):396–404.PubMed
7.
Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179–84.CrossRefPubMed
8.
Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45(1):111–9.CrossRefPubMed
9.
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48–62.CrossRefPubMed
10.
Larson R, Capili B, Eckert-Norton M, Colagreco JP, Anastasi JK. Disorders of glucose metabolism in the context of human immunodeficiency virus infection. J Am Acad Nurse Pract. 2006;18(3):92–103.PubMedCrossRef
11.
Gallagher DM. Current clinical issues impacting the lives of patients living with HIV/AIDS. J Assoc Nurses AIDS Care. 2007;18(1):S11–6.PubMedCrossRef
12.
Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S, Committee ITIC. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. Aids. 2007;21(18):2445–53.PubMedCrossRef
13.
Nigatu T. Integration of HIV and noncommunicable diseases in health care delivery in low-and middle-income countries. Preve Chronic Dis. 2012;9:E93.
14.
15.
16.
Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009–2010. BMJ Open Diabetes Res Care. 2017;5(1):e000304.PubMedPubMedCentralCrossRef
17.
Monroe AK, Glesby MJ, Brown TT. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2014;60(3):453–62.PubMedCrossRef
18.
Capeau J, Bouteloup V, Katlama C, Bastard J-P, Guiyedi V, Salmon-Ceron D, Protopopescu C, Leport C, Raffi F, Chêne G. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. Aids. 2012;26(3):303–14.PubMedCrossRef
19.
Nduka CU, Stranges S, Kimani PK, Sarki AM, Uthman OA. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes/Metab Res Rev. 2017;33(6):e2902.CrossRef
20.
Akgün KM, Gordon K, Pisani M, Fried T, McGinnis KA, Tate JP, Butt AA, Gibert CL, Huang L, Rodriguez-Barradas MC. Risk factors for hospitalization and medical intensive care unit (MICU) admission among HIV infected Veterans. J Acquir Immune Defic Syndr. 2013;62(1):52.PubMedPubMedCentralCrossRef
21.
Medapalli R, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, Rimland D, Rodriguez-Barradas MC. Chang C-CH, Justice AC: comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr. 2012;60(4):393.PubMedPubMedCentralCrossRef
22.
Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis. 2012;59(5):628–35.CrossRefPubMed
23.
World Health Organization. WHO STEPS instrument (core and expanded). The WHO STEPwise approach to noncommunicable disease risk factor surveillance. Geneva: World Health Organization; 2010.
24.
World Health Organization. WHO STEPS instrument. Geneva: World Health Organization; 2012.
25.
Organization WH: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. 2006.
26.
WHO. Waist circumference and waist-hip ratio: report of a WHO Expert Consultation, Geneva, 8–11 December 2008. Geneva: WHO; 2011.
27.
Detection NCEPEPo, Adults ToHBCi: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): International Medical Pub; 2002.
28.
29.
WHO. Diabetes country profles. Geneva: WHO; 2016.
30.
Endris T, Worede A, Asmelash D. Prevalence of diabetes mellitus, prediabetes and its associated factors in Dessie Town, Northeast Ethiopia: a community-based study. Diabetes Metab Syndr Obes. 2019;12:2799–809.PubMedPubMedCentralCrossRef
31.
Tesfaye B, Alebel A, Gebrie A, Zegeye A, Tesema C, Ferede A, Abera H, Alam K. Prevalence of diabetes mellitus and its association with hypertension in Ethiopia: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2019;156:107838.PubMedCrossRef
32.
Brown T, Cole S, Li X, Kingsley L, Palella F, Riddler S. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(21):2541.CrossRef
33.
Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, Young M, Justman JE. Antiretroviral therapy exposure and incidence of diabetes mellitus in the women’s interagency HIV Study. Aids. 2007;21(13):1739–45.PubMedCrossRef
34.
Silva E, Bassichetto K, Lewi D. Lipid profile, cardiovascular risk factors and metabolic syndrome in a group of AIDS patients. Arq Bras Cardiol. 2009;93(2):113–8.PubMedCrossRef
35.
Ataro Z, Ashenafi W, Fayera J, Abdosh T. Magnitude and associated factors of diabetes mellitus and hypertension among adult HIV-positive individuals receiving highly active antiretroviral therapy at Jugal hospital, Harar, Ethiopia. HIV/AIDS. 2018;10:181.
36.
Fiseha T, Belete AG. Diabetes mellitus and its associated factors among human immunodeficiency virus-infected patients on anti-retroviral therapy in Northeast Ethiopia. BMC Res Notes. 2019;12(1):372.PubMedPubMedCentralCrossRef
37.
Mohammed AE, Shenkute TY, Gebisa WC. Diabetes mellitus and risk factors in human immunodeficiency virus-infected individuals at Jimma University Specialized Hospital, Southwest Ethiopia. Diabetes Metab Synd Obes. 2015;8:197.CrossRef
38.
Sachithananthan V, Loha E, Gose M. Prevalence of diabetes mellitus, hypertension and lipodystrophy in HAART receiving HIV patients in Southern Ethiopia. Int STD Res Rev. 2013;1:1–11.CrossRef
39.
Feleke Y, Fekade D, Mezegebu Y. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients. Ethiop Med J. 2012;50(3):221–30.PubMed
40.
Abebe SM, Getachew A, Fasika S, Bayisa M, Demisse AG, Mesfin N. Diabetes mellitus among HIV-infected individuals in follow-up care at University of Gondar Hospital, Northwest Ethiopia. BMJ Open. 2016;6(8):e011175.PubMedPubMedCentralCrossRef
41.
Omech B, Sempa J, Castelnuovo B, Opio K, Otim M, Mayanja-Kizza H, Colebunders R, Manabe YC. Prevalence of HIV-associated metabolic abnormalities among patients taking first-line antiretroviral therapy in Uganda. Isrn Aids. 2012;2012:960178.PubMedPubMedCentralCrossRef
42.
Divala OH, Amberbir A, Ismail Z, Beyene T, Garone D, Pfaff C, Singano V, Akello H, Joshua M, Nyirenda MJ. The burden of hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in HIV care: consequences for integrated services. BMC Public Health. 2016;16(1):1243.PubMedPubMedCentralCrossRef
43.
Rücker SCM, Tayea A, Bitilinyu-Bangoh J, Bermudez-Aza EH, Salumu L, Quiles IA, Szumilin E, Chirwa Z, Rick F, Maman D. High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi. AIDS. 2018;32(2):253.
44.
Shankalala P, Jacobs C, Bosomprah S, Vinikoor M, Katayamoyo P, Michelo C. Risk factors for impaired fasting glucose or diabetes among HIV infected patients on ART in the Copperbelt Province of Zambia. J Diabetes Metab Disord. 2017;16(1):29.PubMedPubMedCentralCrossRef
45.
Diouf A, Cournil A, Ba-Fall K, Ngom-Guèye NF, Eymard-Duvernay S, Ndiaye I, Batista G, Guèye PM, Bâ PS, Taverne B. Diabetes and hypertension among patients receiving antiretroviral treatment since 1998 in Senegal: prevalence and associated factors. Isrn Aids. 2012;2012:621565.PubMedPubMedCentralCrossRef
46.
Maganga E, Smart LR, Kalluvya S, Kataraihya JB, Saleh AM, Obeid L, Downs JA, Fitzgerald DW, Peck RN. Glucose metabolism disorders, HIV and antiretroviral therapy among Tanzanian adults. PLoS ONE. 2015;10(8):e0134410.PubMedPubMedCentralCrossRef
47.
Ngu RC, Choukem S-P, Dimala CA, Ngu JN, Monekosso GL. Prevalence and determinants of selected cardio-metabolic risk factors among people living with HIV/AIDS and receiving care in the South West Regional Hospitals of Cameroon: a cross-sectional study. BMC Res Notes. 2018;11(1):305.PubMedPubMedCentralCrossRef
48.
Husain NE, Noor SK, Elmadhoun WM, Almobarak AO, Awadalla H, Woodward CL, Mital D, Ahmed MH. Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten. HIV/AIDS. 2017;9:193.
49.
Tripathi A, Liese A, Jerrell J, Zhang J, Rizvi A, Albrecht H, Duffus W. Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time. Diabet Med. 2014;31(10):1185–93.CrossRefPubMed
50.
Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, Leaf D, Justice AC. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23(10):1227.PubMedCrossRef
51.
Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep. 2012;9(3):206–17.CrossRefPubMed
52.
53.
Boissonnet C, Schargrodsky H, Pellegrini F, Macchia A, Marcet Champagne B, Wilson E, Tognoni G. Educational inequalities in obesity, abdominal obesity, and metabolic syndrome in seven Latin American cities: the CARMELA Study. Eur J Cardiovasc Prev Rehabil. 2011;18(4):550–6.CrossRefPubMed
54.
Monteiro CA, Conde WL, Lu B, Popkin BM. Obesity and inequities in health in the developing world. Int J Obes. 2004;28(9):1181–6.CrossRef
55.
Hejazi N, Rajikan R, Choong CLK, Sahar S. Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey. BMC Public Health. 2013;13(1):758.PubMedPubMedCentralCrossRef
56.
Adewole O, Eze S, Betiku Y, Anteyi E, Wada I, Ajuwon Z, Erhabor G. Lipid profile in HIV/AIDS patients in Nigeria. Afr Health Sci. 2010;10(2):144–9.PubMedPubMedCentral
57.
Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care. 2007;30(1):113–9.PubMedCrossRef
58.
Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73(4):327–39.PubMedCrossRef
Metadata
Title
Diabetes mellitus and its associated risk factors in patients with human immunodeficiency virus on anti-retroviral therapy at referral hospitals of Northwest Ethiopia
Authors
Alemu Gebrie
Bekele Tesfaye
Tensae Gebru
Fentahun Adane
Worku Abie
Mekonnen Sisay
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2020
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-020-00527-1

Other articles of this Issue 1/2020

Diabetology & Metabolic Syndrome 1/2020 Go to the issue

Review

Mechanism of increased risk of insulin resistance in aging skeletal muscle

Research

Whether the risk of gestational diabetes mellitus is affected by TNF-α, IL-6, IL-10 or ADIPOQ polymorphisms: a meta-analysis

Research

Health literacy and glycemic control in patients with diabetes: a tertiary care center study in Brazil

Research

Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus

Research

Compromised browning plasticity of primary subcutaneous adipocytes derived from overweight Chinese adults

Research

Gender differences in quality of life in adults with long-standing type 1 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits